HIV INFECTIONS

This early-stage trial is testing a new HIV vaccine booster called VRIPRO, given with an immune-boosting adjuvant, in 40 healthy adults aged 18-60 who previously received an HIV vaccine in the HVTN 706 study. Participants will get three shots over 24 weeks. The main goals are to …

This study tests a new long-acting injectable drug called VH4524184 in healthy adults to see if it is safe and how the body handles it. The goal is to find a dose that could one day help control HIV with fewer shots. About 268 volunteers will receive either the drug or a placebo …

This study tests whether dasatinib, a drug used for leukemia, can reduce the hidden HIV reservoir in people whose virus is already suppressed by antiretroviral therapy (ART). Fourteen adults on ART for at least 4 years will be randomly assigned to take dasatinib or a placebo dail…

This study in Botswana tests whether giving three powerful antibodies by infusion can help children who started HIV treatment early keep the virus suppressed without taking daily antiretroviral pills. About 41 children aged 2 to 12 will receive the antibodies while stopping their…

This trial tests a program called WeCare, which combines problem-solving therapy with support for taking HIV medication. It is designed for men who have sex with men (MSM) in South Africa. The study will enroll 60 participants to see if the program reduces depression and anxiety,…

This study tests four approaches to help adults with drug-resistant tuberculosis and HIV stick to their treatments. Participants receive either standard care, counseling, phone reminders via a special pill bottle, or both counseling and reminders. The goal is to see which method …

This study tests a long-acting injectable HIV medication (CAB LA + RPV LA) in people whose virus is still detectable despite taking daily oral pills. About 332 participants will either get the shots or continue standard oral therapy. The goal is to see if the injections can bette…

This study looks at whether the HIV drug cabotegravir is safe for newborns who were exposed to HIV during birth. About 44 healthy babies will receive the drug either by mouth or injection. The goal is to find the right dose and check for side effects, helping to protect these inf…

This study tests a program called Kisoboka for men living with HIV who drink heavily in fishing communities. The goal is to help them drink less, take their HIV medication as prescribed, and achieve undetectable viral loads. About 716 men will be randomly assigned to different co…

This study is testing a new experimental drug called VH4524184 for people with HIV-1 who have never taken HIV medication before. About 150 adults will receive either a low or high dose of VH4524184 along with two standard HIV drugs (emtricitabine and tenofovir alafenamide), or a …

This study tests a program led by trained peers (other women with HIV) that combines acceptance and commitment therapy, exercise, and social support. The goal is to help 300 women in four counties stick to their HIV medication and manage substance use and trauma. Researchers will…

This study tests a new way to help people with HIV in rural Uganda. Traditional healers will be trained to offer HIV testing, counseling, and support to take medication regularly. The goal is to see if this extra help, alongside regular clinic care, can help more people achieve a…

This study looks at whether giving young women (ages 15-24) in Kenya a long-acting injectable HIV medication along with a birth control implant is safe and works well. Researchers will check hormone levels and HIV viral suppression in 700 participants. The goal is to simplify car…

This early-phase trial tests whether specially engineered immune cells (CAR-T cells) can control HIV in people who stop their regular antiretroviral drugs. 18 participants will receive a single infusion of their own modified cells, with some also getting a mild chemotherapy drug …

This study tests different approaches to help people with HIV whose current medication (tenofovir, lamivudine, and dolutegravir, or TLD) is no longer working. It involves 648 adults and teens in Uganda and South Africa. The goal is to find the best strategy to get the virus under…

This study tests whether a team-based program (called ARTAS) helps people with HIV get connected to care after leaving the hospital and reduces the chance of coming back. The team includes infectious disease doctors and social workers who provide support during the hospital stay …

This study tests a mobile app called WiseApp along with a smart pill dispenser to help Spanish-speaking people with HIV take their medication regularly. About 248 participants from New York City and the Dominican Republic will use the app for 12 months. The goal is to see if the …

This study tests whether a same-day HPV screening and treatment approach can help prevent cervical cancer in women living with HIV in the Dominican Republic. 600 women will be randomly assigned to either the new same-day method or standard care. The goal is to see if more women c…

This early-stage study is testing a long-acting injectable HIV prevention drug called cabotegravir, combined with an enzyme (rHuPH20) that helps the drug spread under the skin. The goal is to see if this combination is safe and how the body processes it in 214 healthy adults. Res…

This study tests whether bempedoic acid, a cholesterol-lowering drug, can reduce artery inflammation and improve heart health in people with HIV. About 121 adults aged 40 and older with well-controlled HIV and at least one heart disease risk factor will receive either the drug or…

This study tests whether providing medically tailored meals along with intensive lifestyle coaching can help adults with HIV and type 2 diabetes or prediabetes better manage their weight and blood sugar. About 200 participants will be randomly assigned to receive either the meals…

This study tests whether trained peer recovery specialists can help Black individuals with substance use stick to their long-acting injectable HIV treatment or prevention. 186 participants will either get this peer support or standard care. The goal is to see if the peer program …

This study tests whether a mobile app called Positive Peers can help young people (ages 13-34) with HIV keep the virus under control. About 250 participants who are racial, ethnic, sexual, or gender minorities will use the app and complete surveys over 12 months. The main goal is…

This study aims to help people living with HIV achieve and maintain viral suppression (low virus levels) using a smartphone-based program. It will enroll 1,000 adults who have trouble staying on treatment due to substance use, mental health issues, or other barriers. The program …

This early-stage study tests whether giving two powerful antibodies along with a therapeutic HIV vaccine can help people with HIV control the virus after they stop their daily antiretroviral therapy. The trial enrolls 48 adults in Thailand who started HIV treatment very soon afte…

This study compares two ways to offer cervical cancer screening to women living with HIV: standard clinic-based screening versus adding community outreach where health workers provide HPV self-collection kits at home or in community settings. About 7,600 women across multiple cli…

This study tests whether text messages about HIV prevention, sent to dental patients at community health centers, can increase HIV testing and use of preventive medications like PrEP. About 266 HIV-negative adults with at least one HIV risk factor will receive either HIV-focused …

This study looks at how well people stick to a new HIV prevention shot called lenacapavir. About 3,000 people in the U.S. who want or need HIV prevention will take part. Researchers will track who stays on the shot and how it works in everyday clinic settings.

This study tests a mobile health program called WINGS+PrEP for women who have experienced heavy drinking, partner violence, and involvement with the criminal legal system. The program provides information about PrEP (a daily pill that prevents HIV) and offers support sessions. Re…

This study is developing and testing a virtual reality tool to help young people aged 15-30 who have experienced trauma and are at risk for substance use and HIV. The goal is to see if the tool can reduce substance use and risky behaviors. Researchers are recruiting young men who…

This pilot study tests whether a peer-driven program can help people who inject drugs in Baltimore reduce their risk of HIV, hepatitis C, and overdose. Researchers will identify high-risk injection settings and train peers to promote safer practices, like carrying naloxone and av…

This study aims to make HIV prevention easier to access for underserved groups in Rio de Janeiro, such as gay and bisexual men, transgender women, and sex workers. Instead of requiring clinic visits, participants can get daily PrEP pills and support through community organization…

This study tests a smartphone app called MY-RIDE that offers just-in-time support and nurse-led sessions to help homeless youth reduce substance use and adopt HIV prevention methods like PrEP. 450 participants aged 15-24 who are homeless, use substances, and are sexually active w…

This study looks at two strategies for getting HIV self-test kits and PrEP (a daily pill that prevents HIV) to people who might benefit. Current PrEP users will either directly give kits to friends or refer them to pick up kits. The goal is to see which method gets more people te…

This study tests whether teaching Black male caregivers how to talk about sexual health can help protect Black girls aged 14-18 from HIV, other sexually transmitted infections, and sexual violence. The program involves 612 pairs of girls and their male caregivers. Researchers wil…

This study tests a six-session program called SER Familia for Latino immigrant families with a parent and a child aged 12-17. The program, led by community health workers, aims to reduce stress from adapting to a new culture and build resilience. The goal is to prevent substance …

This study tests whether taking the antibiotic doxycycline shortly after sex can prevent bacterial STIs like syphilis, gonorrhea, and chlamydia. It involves 200 men, transgender women, and travestis in Rio de Janeiro who are at higher risk. Participants choose whether to use doxy…

This study tests a program called TENDAI4PrEP, which uses problem-solving techniques to help pregnant women in Zimbabwe take PrEP, a daily pill that prevents HIV. The program also involves their partners and healthcare providers. Researchers will enroll 132 HIV-negative pregnant …

This study compares two ways of offering HIV prevention medications, hepatitis C treatment, and substance use disorder care to people who inject drugs. Participants will receive services via telehealth and be followed for 12 months. The goal is to see which approach works best fo…

This study is checking the long-term safety and effectiveness of a long-acting injectable drug called cabotegravir (CAB LA) for preventing HIV. It includes about 3,500 people who already received CAB LA in earlier HIV prevention studies. Participants will continue getting the sho…

This study tests whether a text-messaging program can help prevent HIV in cisgender teen boys and young men (ages 13-22) who have sex with men. About 5,000 participants across the US will receive either HIV prevention texts or general healthy lifestyle texts. The goal is to see i…

This study aims to see if training people who inject drugs to become peer educators can help their friends get tested for HIV and use prevention tools like PrEP and treatment for opioid use. About 360 participants from syringe service programs in Maryland will be recruited, along…

This early-stage study tests a new long-acting injectable drug, VH4011499, in 168 healthy adults without HIV. The goal is to see if it is safe and how the body processes it, as a potential future option for HIV prevention. Participants receive one or more doses of the drug or a p…

This study is testing a new program called QUIT-AD to help people living with HIV or tuberculosis (TB) in Cape Town, South Africa, quit smoking. The program combines proven methods to support smoking cessation and improve HIV/TB treatment results. Researchers will enroll 86 daily…

This study tests whether high-intensity interval training (HIIT) or moderate continuous exercise can improve thinking, memory, and daily function in 110 older adults with HIV who are sedentary and fatigued. Participants will exercise three times a week for four months. The goal i…

This study talks to people living with HIV from diverse backgrounds to learn what helps or hinders them from getting oral health care and cancer prevention. Researchers will hold focus groups and use questionnaires to understand barriers and gather ideas for improvement. The goal…

This study looks at how well leg muscles produce energy in older adults (60+) with and without HIV. Researchers will use MRI scans and walking tests to measure muscle metabolism and fatigue. The goal is to understand if metabolic problems in the calf muscle are linked to reduced …

This observational study will follow 2,500 people aged 14–55 who are at risk for HIV across multiple countries. Researchers will track how many new HIV and other sexually transmitted infections occur over time. The goal is to gather data that could help design future studies aime…

This study tests a program to help people safely stop taking long-acting injectable HIV prevention (PrEP). It will enroll 30 HIV-negative adults who are considering stopping or have stopped their PrEP shots. The program includes personalized coaching and, for some, monthly drug l…

This study follows 300 young men who have sex with men (ages 18-24) living with HIV in Ho Chi Minh City, Vietnam, for 12 months. Researchers will track how well they stick to their HIV medication, their viral suppression, mental health, and quality of life. The goal is to underst…

This study will track 1,200 adults in semi-rural Tanzania to find out how common chronic kidney disease (CKD) is and what factors increase the risk. Participants will have blood and urine tests at the start, after 90 days, and again after one year. The goal is to create better wa…

This study looks at how exercise training affects blood pressure and heart rate in people with HIV. Participants will do 12 weeks of supervised strength and aerobic exercises. The goal is to see if regular exercise can improve the body's muscle reflexes and exercise tolerance.

This study looks at how the drug bulevirtide changes gut bacteria and bile acids in people with hepatitis delta (a serious liver infection). Researchers will follow 20 patients for 48 weeks, collecting stool and blood samples to see how these changes relate to liver health. The g…

This study tests whether giving syringe service programs funding and training helps them offer routine HIV and hepatitis C testing to people who inject drugs. About 40 programs will either get this support or just receive a link to CDC resources. The goal is to see if more people…

This study is testing whether an AI-powered chatbot on a smartphone can encourage more men in Malaysia to get tested for HIV. The study will enroll 296 men who have sex with men and have not been tested recently. Participants will use the chatbot and report every 30 days whether …

This study looks back at medical records of 50 adults in France who were diagnosed with HIV between 2021 and 2024. Researchers want to find out if doctors missed signs of HIV during visits in the year before diagnosis. The goal is to understand why testing is delayed and help cat…

This study looks at how HIV affects a natural cell cleanup process called autophagy in people with HIV. Researchers will compare blood cells from 180 participants, including those on HIV medication, rare controllers, and healthy volunteers. The goal is to understand why cell clea…

This study looks at 400 women living with HIV to understand how the bacteria in their gut and vagina might influence HPV infection and cervical changes. Researchers will collect samples to see if an imbalance in vaginal bacteria makes these women more likely to get HPV and develo…

This study follows 120 people with HIV who switch to a long-acting injectable treatment or stay on oral pills. Researchers will measure HIV reservoirs, immune activation, and gut bacteria changes over a year. The goal is to see if injectable therapy reduces inflammation and hidde…

This study looks at the gut bacteria of 132 people with HIV who are 55 or older and have had the virus under control for at least 5 years. Researchers want to see if changes in gut bacteria over time are linked to signs of frailty and other health problems. The goal is to better …

This study looks at whether fungi moving from the gut into the blood can cause inflammation and worsen lung function in people with HIV. Researchers will measure a fungal marker called BDG in blood and urine, and track lung health over three years. The goal is to better understan…